logo

OCTOBER 29-NOVEMBER 2, 2017
COLORADO CONVENTION CENTER
DENVER, COLORADO

Annual Prize Honors a Unique Biomedical Engineer, Scientist, and Cardiologist

NEW YORK – October 12, 2017 - Internationally renowned cardiologist, Elazer Edelman, MD, PhD, will be presented with the TCT Career Achievement Award on Monday, October 30th during the 29th Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver, Colorado. TCT is the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT Directors, Martin B. Leon, MD, and Gregg W. Stone, MD, will present the award.

“We are extremely proud to honor Elazer Edelman with the TCT 2017 Career Achievement Award,” said Dr. Leon, CRF Founder and Co-Director of Medical Research and Education. “Over the course of his distinguished career, he has transformed patient care by bringing together experts from various disciplines to create highly effective and clinically relevant solutions to medical problems. His research, which combines his passion for basic science with practical medical training, has contributed to generations of life-changing devices such as bare-metal and drug-eluting stents.”

A lifelong researcher and innovator, Dr. Edelman and his students have been credited as some of the key contributors and pioneers of the coronary stent. His research examining the cellular and molecular mechanisms that produce atherosclerosis and coronary artery disease critically advanced the development and optimization of the first bare-metal stents and subsequent iterations, including drug-eluting stents. His most recent publications have focused on how tissue engineered cells might be used for the local delivery of growth factors and growth inhibitors in the study of the vascular homeostasis and repair, cancer invasiveness and metastases and the homology between endothelial paracrine and angiocrine regulation in cancer and vascular diseases.

“Dr. Edelman is widely recognized for his vision, leadership, advancement of technological innovations, and novel insights into biomedical pathways and vascular responses,” added Dr. Stone, Co-Director of Medical Research and Education at CRF. “Along with his extensive academic, clinical, and medical pursuits, he has devoted a significant amount of his career to mentoring the next generation of researchers and clinicians.”

Dr. Edelman’s research integrates multiple disciplines including polymer based controlled and modulated drug delivery; growth factor biology and biochemistry; tissue engineering; biomaterials-tissue interactions and the vascular response to injury. He has been deeply devoted to the education and training of colleagues and future generations by mentoring more than 350 graduate students and postdoctoral fellows. He has also authored or co-authored nearly 300 original scientific publications.

Dr. Edelman is currently the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at the Massachusetts Institute of Technology (MIT) and is a core member of the Institute for Medical Engineering and Science (IMES). He is a Professor of Medicine at Harvard Medical School and Senior Attending Physician at Brigham and Women’s Hospital. Dr. Edelman also directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.

Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and Applied Biology from MIT, a Masters of Science degree in Electrical Engineering and Computer Sciences from MIT, a degree in medicine from Harvard Medical School and a PhD in Medical Engineering and Medical Physics from MIT. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems.  

After receiving his degrees, he completed an internship and residency in Internal Medicine and fellowship in Cardiovascular Medicine, all at the Brigham and Women's Hospital. He subsequently spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair.

Dr. Edelman is a fellow of the American College of Cardiology, American Heart Association, American Institute for Medical and Biological Engineering, American Society for Clinical Investigation, American Academy of Arts and Sciences, National Academy of Medicine, National Academy of Engineering and National Academy of Inventors. As Chief Scientific Advisor of Science: Translational Medicine and member of the FDA Scientific Board, he has set the tone for the national debate on translational research and innovation.

Previous winners of the TCT Career Achievement Award include: Geoffrey O. Hartzler, MD; David R. Holmes, MD; Patrick W. Serruys, MD, PhD; John B. Simpson, MD; Antonio Colombo, MD; Julio C. Palmaz, MD; Donald S. Baim, MD; William W. O’Neill, MD; J. Eduardo M.R. Sousa, MD, PhD; Eugene Braunwald, MD; James T. Willerson, MD; Paul Yock, MD; Barry T. Katzen, MD; Seung-Jung Park, MD; Spencer B. King III, MD; Alain G. Cribier, MD;  Eric J. Topol, MD; Renu Virmani, MD; Andreas Gruentzig, MD; Michael J. Mack, MD; John E. Abele; and Runlin Gao, MD.

The TCT Career Achievement Award will be presented on Monday, October 30, 2017 at 9:45 AM MT in the Main Arena (Bellco Theater) of the Colorado Convention Center in Denver, Colorado.

Geoffrey O. Hartzler Master Clinical Operator Award

ANNOUNCING THE WINNER OF THE MASTER CLINICAL OPERATOR AWARD … ALEC VAHANIAN, MD

The Geoffrey O. Hartzler Master Clinical Operator Award will be presented to Alec Vahanian, MD, on October 31st at TCT 2017. The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and innovation. TCT Co-Directors, Martin B. Leon, MD, and Gregg W. Stone, MD, will present the award.

Dr. Vahanian is widely acknowledged for his extensive knowledge and expertise in percutaneous valve interventions, antithrombotic treatments, and valvular heart disease, specifically the evaluation, surgical management, and transcatheter valve interventions of both the aortic and mitral valves. His group performed the first percutaneous mitral commissurotomy in Europe and has amassed more than 30 years of follow-up data in this area. They were among the first in France to perform transcatheter aortic valve replacement and transcatheter mitral valve repair, including the implantation of a TAVR valve in a failing valve prosthesis or surgical annuloplasty or severe mitral annular calcification using the transseptal route. Dr. Vahanian also participated in the first studies on thrombolysis and percutaneous coronary intervention during STEMI through the GUSTO trial study group.

“We are extremely honored to pay tribute to Dr. Vahanian,” said Dr. Leon, CRF Founder and Co-Director of Medical Research and Education. “He has a remarkable devotion to patient care, an incredible work ethic, and a desire to continually improve and refine interventional procedures. Throughout his career, Alec has truly embraced innovation and international collaboration to help bring new, more effective ways to treat patients.”

Dr. Vahanian is known for applying an integrated approach to cardiology for the benefit of his colleagues and patients. In recent years, he has dedicated his efforts to building educational materials based on guidelines. He was the Chairman of the Guidelines Task Force on Valvular Heart Disease for the European Society of Cardiology (ESC) in 2007 and 2012, and was the Chairman of its Education Committee from 2012 through 2016. He is currently Chairman of the ESC’s European Observational Registry Program where he hopes to evaluate the quality of guidelines using registries with the aim of improving future guidelines.

“Alec is a premier technical and clinical operator with an extraordinary ability to take new technologies and find creative ways to advance and perfect interventional procedures. Patient care has always been his primary focus and he always strives to provide the best care for his patients. In addition, he has been instrumental in leading the European valve guidelines and documenting the practice of valve therapeutics across the European continent,” said Dr. Stone, Co-Director, Medical Research and Education at CRF.

Dr. Vahanian is currently Head of the Cardiology Department at Bichat-Claude Bernard Hospital in Paris and Professor of Cardiology at University Paris VII. A member of the board of the European Society of Cardiology and other professional organizations, he is also an associate editor of the European Heart Journal and a co-editor of EuroIntervention. In addition, he serves on the editorial board of various journals including the Archives of Cardiovascular Diseases, Current Cardiology Reports, JACC Intervention, F1000, Nature Clinical Reviews, Circulation (French Edition), BMJ Case Reports, and Structural Heart: The Journal of the Heart Team. He has authored more than 450 publications in top-tier medical journals, contributed to almost 50 books, and delivered nearly 600 lectures around the world.

Dr. Vahanian began his medical career soon after completing his medical education and cardiology residency in Paris. He became Chef de Clinique at University Paris VI in 1979, and Professor of Cardiology in 1988. He served as Head of Cardiology at Hospital Tenon from 1994 to 1999 and has been Head of Cardiology at Hospital Bichat since 1999.

Award Presentation
Tuesday, October 31, 2017
9:45 AM in the Main Arena (Bellco Theater)

Please contact Monique Sylvester at to reserve a hotel room or modify your existing reservation.

Program Available Online

NEW YORK, NY – September 27, 2017 – The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2 in Denver, Colorado.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Monday, October 30; Tuesday, October 31; Wednesday, November 1; and Thursday, November 2.

The complete agenda for TCT 2017 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty on the TCT Web site.

Media are invited to attend TCT. If you are unable to attend in person, you may still cover it remotely via Virtual TCT. Registering as media ensures that you have access to all the press conferences, trial data, abstracts, and press releases. More information on press credentials and guidelines can be found at http://www.crf.org/tct/press/press-credentials-and-guidelines. To apply for press credentials, visit: http://www.crf.org/tct/press/press-registration-form.

Monday, October 30, 2017

7:30 AM - 9:15 AM

Moderator: Roxana Mehran, MD

Discussants: David J. Cohen, MD; Cindy L. Grines, MD; Jonathan M. Hill, MD; Leif Thuesen, MD

7:30 AM
CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock
Holger Thiele, MD

7:45 AM
EXCEL QOL: Quality of Life After PCI vs CABG in Left Main Coronary Artery Disease
Suzanne J. Baron, MD

8:00 AM

DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions
Shao-Liang Chen, MD, PhD

8:15 AM

HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease
Vladimir Ganyukov, MD, PhD

8:30 AM

HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs a Durable Polymer-Based DES in Patients With Coronary Artery Disease
Mitchell W. Krucoff, MD

8:45 AM

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis
Jose P.S. Henriques, MD

9:00 AM

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque
Kiyoshi Hibi, MD

Tuesday, October 31, 2017
7:30 AM - 9:30 AM

Moderator: Ori Ben-Yehuda, MD

Discussants: Wayne B. Batchelor, MD, MHS; George D. Dangas, MD, PhD; Allen Jeremias, MD, MSc; Duane S. Pinto, MD, MPH

7:30 AM

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease
Stephen G. Ellis, MD

7:45 AM

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease
Bernard R. Chevalier, MD

8:00 AM

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis
David J. Cohen, MD, MSc

8:15 AM

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease
Gregg W. Stone, MD

8:30 AM

CrossBoss First: A Randomized Trial of Antegrade Dissection and Re-entry vs Standard Wire Escalation for Crossing Coronary Artery Chronic Total Occlusions
Emmanouil S. Brilakis, MD

8:45 AM

REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions
Kambis Mashayekhi, MD

9:00 AM

FAVOR II China: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio in Patients With Coronary Artery Disease
Xu Bo, MBBS

9:15 AM

FAVOR II Europe Japan: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio in Patients With Coronary Artery Disease
Jelmer Westra, MS

Wednesday, November 1, 2017
7:30 AM - 9:30 AM

Moderator: Gary S. Mintz, MD

Discussants: Gorav Ailawadi, MD; Jeffrey S. Borer, MD; Dean J. Kereiakes, MD; Anna Sonia Petronio, MD

7:30 AM

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years
Olivier Varenne, MD, PhD

7:45 AM

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI
Elvin Kedhi, MD, PhD

8:00 AM

REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS
Harry Suryapranata, MD, PhD

8:15 AM

MITRAL: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings
Mayra Guerrero, MD

8:30 AM

INTREPID: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation
Paul Sorajja, MD

8:45 AM

TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation
David W.M. Muller, MBBS, MD

9:00 AM

TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair in Patients With Severe Primary Mitral Regurgitation
James S. Gammie, MD

9:15 AM

MAVERIC: 6-Month Outcomes of Transcatheter MV Repair in Patients With Severe Secondary Mitral Regurgitation
Stephen G. Worthley, MBBS, PhD

Thursday, November 2, 2017
7:30 AM - 8:45 AM

Moderator: Ajay J. Kirtane, MD, SM

Discussants: C. Michael Gibson, MS, MD; Jonathan M. Hill, MD; Jacqueline Saw, MD; Molly Szerlip, MD; Robert W. Yeh, MD

7:30 AM

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Non-Valvular Atrial Fibrillation
Vivek Y. Reddy, MD

7:45 AM

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease
Rasha Al-Lamee, MD

8:00 AM

FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease
William F. Fearon, MD

8:15 AM
TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation
Georg Nickenig, MD

8:30 AM
FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation
Susheel K. Kodali, MD

Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.